Prelude Therapeutics Ratios (2024-2025) | PRLD

Ratios Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -1,145.87%-845.78%-314.12%
EBIT Margin -1,145.87%-845.78%-314.12%
EBITDA Margin -1,060.47%-721.58%-303.42%
Operating Margin -1,145.87%-845.78%-314.12%
Net Margin -1,145.87%-845.78%-314.12%
FCF Margin -911.97%-519.93%-294.08%
Efficiency
Assets Average 235.70M210.76M186.37M158.39M128.09M104.84M
Equity Average 196.50M169.35M143.94M117.32M89.51M67.19M
Invested Capital 210.73M182.28M156.43M131.46M103.18M75.84M58.53M
Asset Utilization Ratio 0.040.040.050.10
Leverage & Solvency
Equity Ratio 0.850.810.790.750.730.660.62
Valuation
Enterprise Value -205.97M-183.89M-157.67M-137.66M-161.91M-124.76M-65.62M
Return Ratios
Return on Sales -11.46%-8.46%-9.74%-9.74%-3.14%
Return on Assets -0.37%-0.43%-0.53%-0.52%
Return on Equity -0.47%-0.58%-0.76%-0.81%